** Shares of medical device maker Dexcom DXCM.O rise 8.6% to $72.60 premarket
** Co says U.S. FDA has cleared its 15-day continuous glucose monitoring (CGM) device called Dexcom G7 15 Day for people over the age of 18 with diabetes in the United States
** Co says the CGM lasts for 15.5 days and helps in "easier glucose management with fewer monthly sensors and reduced monthly waste"
** Co's other G7 CGM lasts for up to 10 days, while its over-the-counter CGM Stelo also lasts for 15 days
** Approval for co's 15-day CGM should provide momentum through 2025, brokerage William Blair had said in a note in February
** Up to last close, stock had fallen 14.1% YTD
(Reporting by Sneha S K )
(( Sneha.SK@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.